Analysis suggests risk of suicidal ideation associated with semaglutide
An analysis of a global database documenting adverse drug reactions has detected a disproportional occurrence of suicidal ideation associated with use of the glucagon‐like peptide‐1 (GLP‐1) receptor agonist semaglutide. This association was not present with use of the GLP‐1 receptor agonist liraglutide or with other medications used to treat type 2 diabetes or obesity. Study results were published online Aug. 20, 2024 in JAMA Network Open .
Publication Details
- Journal
- The Brown University Psychopharmacology Update
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1002/pu.31236
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00